Show simple item record

dc.contributor.authorSharma, Anand
dc.contributor.authorBabra, Deshveer
dc.contributor.authorJoshi, Priya
dc.contributor.authorHall, Marcia
dc.contributor.authorGogbashian, Andrew
dc.contributor.authorVasdev, Nikhil
dc.contributor.authorJoseph, Magdalene
dc.contributor.authorYazdan, Amir
dc.contributor.authorKanfer, Edward
dc.date.accessioned2020-11-27T12:00:01Z
dc.date.available2020-11-27T12:00:01Z
dc.date.issued2020-11
dc.identifier.citationSharma , A , Babra , D , Joshi , P , Hall , M , Gogbashian , A , Vasdev , N , Joseph , M , Yazdan , A & Kanfer , E 2020 , ' Survival Outcomes After High-dose Chemotherapy and Stem Cell Transplantation in the Salvage Setting for Relapsed or Refractory Germ Cell Cancers ' , In VIVO - International Journal of Experimental and Clinical Pathophysiology and Drug Research , vol. 34 , no. 6 , pp. 3675-3679 . https://doi.org/10.21873/invivo.12215
dc.identifier.issn1791-7549
dc.identifier.urihttp://hdl.handle.net/2299/23525
dc.description© 2020 The Author(s). The unrestricted non-commercial use, distribution and reproduction in any medium of CGP articles for academic reasons is allowed, provided that the original work is properly cited.
dc.description.abstractBackground/Aim: High-dose chemotherapy (HDCT) and stem cell transplantation (SCT) have been established as the standard of care in patients with relapsed germ cell tumours (GCTs). We evaluated the safety, efficacy and tolerability of HDCT/ SCT in patients with relapsed GCTs. Patients and Methods: Twenty-eight patients with relapsed GCTs, treated with HDCT, were included in this study. The conditioning regime was carboplatin, etoposide, cyclophosphamide and paclitaxel. Clinical, radiological imaging and tumour markers determined treatment outcomes. Results: Median age was 35 years (range=21-57 years) with 26 males and 2 females. Median time to first relapse was 6 months. Median time to progression after 2nd line chemotherapy was 17.3 months. Fourteen patients had peripheral neurotoxicity (≥Grade 2) (50%), 4 patients developed renal failure, 5 had ototoxicity (≥Grade 2) and 1 patient developed acute myeloid leukaemia. Median survival was 62 months and 16 patients (57%) are in clinical follow-up with surveillance. Conclusion: In relapsed GCT patients, median survival may exceed 5 years post-HDCT and SCT.en
dc.format.extent5
dc.format.extent109332
dc.language.isoeng
dc.relation.ispartofIn VIVO - International Journal of Experimental and Clinical Pathophysiology and Drug Research
dc.subjectHigh dose chemotherapy
dc.subjectRelapsed germ cell cancer
dc.subjectStem cell transplant
dc.subjectSurvival
dc.subjectGeneral Biochemistry,Genetics and Molecular Biology
dc.subjectPharmacology
dc.titleSurvival Outcomes After High-dose Chemotherapy and Stem Cell Transplantation in the Salvage Setting for Relapsed or Refractory Germ Cell Cancersen
dc.contributor.institutionDepartment of Clinical and Pharmaceutical Sciences
dc.contributor.institutionCentre for Health Services and Clinical Research
dc.contributor.institutionBasic and Clinical Science Unit
dc.contributor.institutionExtracellular Vesicle Research Unit
dc.contributor.institutionSchool of Life and Medical Sciences
dc.contributor.institutionDepartment of Clinical, Pharmaceutical and Biological Science
dc.description.statusPeer reviewed
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85095602214&partnerID=8YFLogxK
rioxxterms.versionofrecord10.21873/invivo.12215
rioxxterms.typeJournal Article/Review
herts.preservation.rarelyaccessedtrue


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record